{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:38:34Z","timestamp":1790109514863,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["25K02769"],"award-info":[{"award-number":["25K02769"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K12501"],"award-info":[{"award-number":["24K12501"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Open Science"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euros.2025.12.012","type":"journal-article","created":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T19:22:20Z","timestamp":1766776940000},"page":"158-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Integrated Assessment of Percentage \u03b12,3-Linked Sialylated Prostate-specific Antigen and the Prostate Health Index with Magnetic Resonance Imaging for Detection of Clinically Significant Prostate Cancer"],"prefix":"10.1016","volume":"83","author":[{"given":"Takuya","family":"Oishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Hamaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotake","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jotaro","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Ohyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0026-4079","authenticated-orcid":false,"given":"Shingo","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euros.2025.12.012_b0005","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/MED.0b013e328360332a","article-title":"Prostate cancer overdiagnosis and overtreatment","volume":"20","author":"Klotz","year":"2013","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.euros.2025.12.012_b0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s10147-016-1049-y","article-title":"Recent progress and perspectives on prostate cancer biomarkers","volume":"22","author":"Hatakeyama","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euros.2025.12.012_b0015","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/iju.15545","article-title":"Japanese clinical practice guidelines for prostate cancer 2023","volume":"31","author":"Kohjimoto","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2025.12.012_b0020","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s12875-024-02688-8","article-title":"PSA testing in primary care: is it time to change our practice?","volume":"25","author":"Denijs","year":"2024","journal-title":"BMC Prim Care"},{"key":"10.1016\/j.euros.2025.12.012_b0025","doi-asserted-by":"crossref","first-page":"31345","DOI":"10.1038\/s41598-024-82821-w","article-title":"Prostate-specific antigen testing in the United States during 2008\u20132022 in relation to the US preventive services task force recommendations","volume":"14","author":"Merrill","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.euros.2025.12.012_b0030","doi-asserted-by":"crossref","first-page":"20290","DOI":"10.1038\/s41598-025-06548-y","article-title":"Association of height, BMI, and smoking status with prostate cancer risk before and after the introduction of PSA testing in Sweden","volume":"15","author":"Mboya","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.euros.2025.12.012_b0035","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/bco2.326","article-title":"Variation in harms and benefits of prostate-specific antigen screening for prostate cancer by socio-clinical risk factors: a rapid review","volume":"5","author":"Tesfai","year":"2024","journal-title":"BJUI Compass"},{"key":"10.1016\/j.euros.2025.12.012_b0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.urolonc.2024.05.014","article-title":"Randomized trials of PSA screening","volume":"43","author":"Dave","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2025.12.012_b0045","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/iju.70063","article-title":"Active surveillance in prostate cancer with intermediate-risk features: the PRIAS-JAPAN study","volume":"32","author":"Blas","year":"2025","journal-title":"Int J Urol."},{"key":"10.1016\/j.euros.2025.12.012_b0050","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/iju.15415","article-title":"Comparison of patient background between a real-world North American cohort and the G\u00f6teborg-2 trial","volume":"31","author":"Chiarelli","year":"2024","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2025.12.012_b0055","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1111\/iju.70013","article-title":"Combining percentage prostate-specific antigen reduction and multiparametric magnetic resonance imaging to reduce unnecessary biopsy after focal therapy with high-intensity focused ultrasound for prostate cancer","volume":"32","author":"Hsieh","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2025.12.012_b0060","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1111\/iju.70024","article-title":"Utility of combining Prostate Health Index and magnetic resonance imaging for the diagnosis of prostate cancer","volume":"32","author":"Sekine","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2025.12.012_b0065","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/iju.70193","article-title":"Shifts in diagnostic approaches for prostate cancer: impact of MRI-informed biopsies on low-risk cancer detection","volume":"32","author":"Tohi","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2025.12.012_b0070","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00345-012-0927-9","article-title":"Diagnostic significance of [\u22122]pro-PSA and prostate dimension-adjusted PSA-related indices in men with total PSA in the 2.0\u201310.0 ng\/ml range","volume":"31","author":"Ito","year":"2013","journal-title":"World J Urol"},{"key":"10.1016\/j.euros.2025.12.012_b0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/jcla.21687","article-title":"Stability of [\u22122]pro-PSA in whole blood and serum: analysis for optimal measurement conditions","volume":"28","author":"Igawa","year":"2014","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.euros.2025.12.012_b0080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/JU.0000000000000495","article-title":"Diagnostic impacts of clinical laboratory based p2PSA indexes on any grade, Gleason grade group 2 or greater, or 3 or greater prostate cancer and prostate specific antigen below 10 ng\/ml","volume":"203","author":"Ito","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.euros.2025.12.012_b0085","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/pros.70025","article-title":"Optimizing prostate cancer care: clinical utility of the Prostate Health Index","volume":"85","author":"Lee","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2025.12.012_b0090","doi-asserted-by":"crossref","first-page":"527.e17","DOI":"10.1016\/j.urolonc.2025.05.007","article-title":"Study of AI algorithms on mpMRI and PHI for the diagnosis of clinically significant prostate cancer","volume":"43","author":"Luo","year":"2025","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euros.2025.12.012_b0095","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3390\/ijms18040845","article-title":"Comparative study of blood-based biomarkers, \u03b12,3-sialic acid PSA and PHI, for high-risk prostate cancer detection","volume":"18","author":"Ferrer-Batall\u00e9","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euros.2025.12.012_b0100","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41416-021-01637-x","article-title":"Simultaneous analysis of serum \u03b12,3-linked sialylation and core-type fucosylation of prostate-specific antigen for the detection of high-grade prostate cancer","volume":"126","author":"Hatano","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.euros.2025.12.012_b0105","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/glycob\/cwh071","article-title":"Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy","volume":"14","author":"Ohyama","year":"2004","journal-title":"Glycobiology"},{"key":"10.1016\/j.euros.2025.12.012_b0110","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3390\/ijms18020470","article-title":"An automated micro-total immunoassay system for measuring cancer-associated \u03b12,3-linked sialyl N-glycan-carrying prostate-specific antigen may improve the accuracy of prostate cancer diagnosis","volume":"18","author":"Ishikawa","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euros.2025.12.012_b0115","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/pros.24917","article-title":"The Effects of the blood-based S2,3PSA% test on prostate cancer screening: a novel approach to reduce the need for MRI and unnecessary biopsies","volume":"85","author":"Miura","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2025.12.012_b0120","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/pros.24894","article-title":"Analytical and real-world clinical characterization of S2,3PSA% test in MRI fusion targeted prostate biopsy population","volume":"85","author":"Miura","year":"2025","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2025.12.012_b0125","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1002\/pros.24239","article-title":"Characteristics of \u03b12,3-sialyl N-glycosylated PSA as a biomarker for clinically significant prostate cancer in men with elevated PSA level","volume":"81","author":"Yoneyama","year":"2021","journal-title":"Prostate"},{"key":"10.1016\/j.euros.2025.12.012_b0130","doi-asserted-by":"crossref","unstructured":"Tokunaga T, Nishioka M, Kobayashi K, et al. Diagnostic performance of the novel biomarker S2,3PSA density for prostate biopsy optimization in Prostate Imaging Reporting and Data System 3\u20135 lesions. Prostate. In press. https:\/\/doi.org\/10.1002\/pros.70078.","DOI":"10.1002\/pros.70078"},{"key":"10.1016\/j.euros.2025.12.012_b0135","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2018.07.031","article-title":"Prediction of high-grade prostate cancer following multiparametric magnetic resonance imaging: improving the Rotterdam European Randomized Study of Screening for Prostate Cancer risk calculators","volume":"75","author":"Alberts","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.12.012_b0140","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.eururo.2014.08.011","article-title":"The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men","volume":"66","author":"Vedder","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euros.2025.12.012_b0145","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/bju.13314","volume":"117","author":"Poyet","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.euros.2025.12.012_b0150","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41598-025-86607-6","article-title":"Development and validation of biopsy free nomograms for predicting clinically significant prostate cancer in men with PI-RADS 4 and 5 lesions","volume":"15","author":"Wang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.euros.2025.12.012_b0155","doi-asserted-by":"crossref","first-page":"22816","DOI":"10.1038\/s41598-025-05718-2","article-title":"Combining multi-parametric MRI radiomics features with tumor abnormal protein to construct a machine learning-based predictive model for prostate cancer","volume":"15","author":"Zhang","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.euros.2025.12.012_b0160","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/iju.70075","article-title":"Development, validation, and clinical utility of a nomogram for urological tumors: how to build the best predictive model","volume":"32","author":"Utsumi","year":"2025","journal-title":"Int J Urol"},{"key":"10.1016\/j.euros.2025.12.012_b0165","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41598-020-78428-6","article-title":"The Prostate Health Index aids multi-parametric MRI in diagnosing significant prostate cancer","volume":"11","author":"Fan","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.euros.2025.12.012_b0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.euros.2025.08.004","article-title":"Overview of performance indicators of prostate cancer screening trials","volume":"80","author":"van Harten","year":"2025","journal-title":"Eur Urol Open Sci"},{"issue":"5 Suppl","key":"10.1016\/j.euros.2025.12.012_b0175","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1200\/JCO.2025.43.5_suppl.358","article-title":"S2,3PSA% as a predictor of reclassification of 1st protocol biopsy on active surveillance for early-stage prostate cancer patients: from the PRIAS-JAPAN study","volume":"43","author":"Kato","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["European Urology Open Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325024917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666168325024917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T21:08:43Z","timestamp":1770152923000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666168325024917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":35,"alternative-id":["S2666168325024917"],"URL":"https:\/\/doi.org\/10.1016\/j.euros.2025.12.012","relation":{},"ISSN":["2666-1683"],"issn-type":[{"value":"2666-1683","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated Assessment of Percentage \u03b12,3-Linked Sialylated Prostate-specific Antigen and the Prostate Health Index with Magnetic Resonance Imaging for Detection of Clinically Significant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Open Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euros.2025.12.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}